51 results about "Medication dose" patented technology

Systems, devices and methods are provided for determining a medication dose for a patient or user. The dose determination can account for recent and / or historical analyte levels of the patient or user. The dose determination can also take into account other information about the patient or user, such as physiological information, dietary information, activity, and / or behavior. Many different dose determination embodiments are set forth, pertaining to a wide array of different aspects of the system or environment in which the embodiments can be implemented.

The invention discloses a method for adjusting administration dosage according to adverse reaction risk based on a joint model, and is applied to the field of intelligent medical treatment. In the prior art, the relationship between the sirolimus steady-state valley concentration and the specific adverse reaction cannot be quantified, so that the defect of lack of accurate guidance for clinical medication is caused. Through systematic research, the method determines the individual target valley concentration range through a BKMR model for the first time, obtains individual pharmacokinetic parameters of a patient through a group pharmacokinetic model, and finally determines the medication time and the medication dosage of the patient through Bayesian negative feedback simulation, and the medication time and the medication dosage are used for adjusting a medication scheme. According to the invention, prospective risk prediction of adverse reactions of sirolimus is realized, the treatment safety of children with vascular diseases is remarkably improved, and long-term prognosis of patients is improved.

The invention discloses a bedridden patient sign measurement and medication assisting system based on multi-sensor fusion, which belongs to the technical field of medical instruments and comprises a multi-sensor fusion measurement module, a self-adaptive calibration compensation module, an intelligent evaluation decision module, a medication assisting calculation module and a closed-loop feedback optimization module. A pressure sensor array, an ultrasonic sensor and an acceleration sensor are used for cooperatively measuring the height and weight of a patient, a deformation compensation model and a body position correction model are adopted for accurate calibration, a BMI index is automatically calculated, a VTE risk score, a falling risk score and a self-care ability score are generated, and the medication dosage is intelligently recommended according to medicine characteristics and patient physique. And continuously optimizing system parameters through an incremental learning algorithm to form a measurement-evaluation-medication-optimization deep coupling closed-loop system, so that the physical sign measurement precision, clinical evaluation efficiency and medication safety of the bedridden patient are remarkably improved, and the nursing labor intensity and the medical error risk are reduced.

The utility model relates to an ointment dosing device capable of dosing quantitatively, which solves the problems that the dosage can not be stably controlled, the ointment can not be daubed uniformly and the sanitation can not be guaranteed in the existing ointment daubing mode. The device comprises a front-back through outer sleeve, a push rod is arranged in the outer sleeve in a sliding and penetrating mode, an elastic buckle is arranged on one side of the rear end of the outer sleeve, a plurality of clamping steps corresponding to the elastic buckle are arranged on the rear portion of the push rod, and a silicon rubber sleeve is arranged at the front end of the push rod in a sleeved mode. The gear of the push rod can be adjusted according to different drug dosages, quantitative drug delivery is achieved, in the drug delivery process, a very small amount of ointment adheres to the inner wall of the outer sleeve, waste is reduced, finally, the silica gel sleeve is adopted for isolation to evenly smear the ointment, and cross infection is avoided.

This invention belongs to the field of intelligent healthcare, specifically relating to a personalized dosing method for sirolimus combined with voriconazole in the treatment of PID in children. The method includes: obtaining the age of the PID child; determining the sirolimus dosage when combined with voriconazole based on the PID child's age; if the PID child's age is in the range of [1, 6) years, the dosage is [0.100, 0.330] mg / QD; if the age is in the range of [6, 13) years, the dosage is [0.280, 0.540] mg / QD. This application is the first to develop a PPK model for PID children using sirolimus combined with voriconazole (VRC), and based on the PPK, explores the optimal dosage for PID children using sirolimus combined with VRC, providing concise dosage guidance for children of different age groups; and through posterior Bayesian methods, it can provide individualized sirolimus medication guidance.

This invention relates to a highly active effective fraction of the Epiglottis-Clearing Decoction and its application in the preparation of antitussive drug compositions, belonging to the field of traditional Chinese medicine extract technology. The effective fraction contains hydroxysaffron yellow A, paeoniflorin, naringin, and neohesperidin, with the total content of these four components not less than 20% of the total mass of the effective fraction. The effective fraction of this invention is prepared by purification with macroporous resin. Compared with the freeze-dried powder of the traditional Epiglottis-Clearing Decoction, the total content of the four active ingredients is increased from 3.32% to 20.87%, achieving a more than 6-fold high-efficiency enrichment. Animal pharmacodynamic experiments show that the antitussive effect of a low dose (275.5 mg / kg) of this effective fraction is comparable to that of the freeze-dried powder of the original decoction (1928 mg / kg), reducing the dosage to about 1 / 7 of the original formula, demonstrating a significant "synergistic effect with reduced dosage" technical effect. The effective active ingredients provided by this invention have a clear content and stable quality, and can be made into modern preparations such as tablets, capsules or granules, solving the problems of large volume, inaccurate dosage and poor patient compliance of traditional decoctions.

The application relates to a zero-character full-symbol medication guidance system based on a fool-proof design, and belongs to the technical field of medical safety. The system comprises seven pure graphical symbol modules of medication frequency, medication time, medication dose, medication route, contraindication warning, adverse reaction treatment and missed medication treatment. The modules are visually distinguished by unified color, shape and line type, and are combined into a complete information chain in a fixed order of frequency, time, dose, route, contraindication, adverse reaction and missed medication, and are printed or displayed on a medicine box, a medication guidance sheet or a prescription carrier. The application migrates the picture priority and fool-proof and error-proof operation national standard system in the construction industry to a medical medication scene, fundamentally eliminates medication misreading risks caused by ambiguous characters, character ambiguity and cultural level differences, realizes the instinctive recognition and accurate execution of the whole population such as illiterates, the elderly with low vision and cognitive impairment, and has the remarkable technical effects of zero learning cost, full-process coverage and low cost and easy popularization.

A system and method are provided for remotely supervised preparation, verification, and controlled dispensing of medication doses at geographically distributed remote dispensing units. A recipient and a supervisor are authenticated. A real-time audiovisual session is established between the recipient and at least the supervisor, and additional authenticated participants may join without authority to actuate dose release. The system receives an electronic medication order and corresponding label data originating from an external clinical information system and authorizes preparation of doses at the remote dispensing unit based on the order. Prior to any release, verification data is presented to the supervisor. A controlled mechanical transfer mechanism is actuated to release a prepared dose to the recipient only after verification and affirmative authorization by an authenticated supervisor. The disclosed systems and methods are applicable to controlled substances and other medications requiring supervised dispensing.

The present application relates to a kind of combined drug composition for improving or treating follicular lymphoma and its application, the active component of the combined drug composition is composed of first active component and second active component;The first active component is selected from any one or combination of at least two of ritanserin or its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from any one or combination of at least two of donepezil or its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combined drug composition has excellent improvement or treatment effect of follicular lymphoma, two active components not only can reduce the dosing of ritanserin or donepezil when inhibiting follicular lymphoma, improve drug safety, but also have more significant inhibiting effect of follicular lymphoma than using single active component, reach the effect of synergistic promotion.

The invention discloses a pregnancy individualized medication dosage prediction factor screening method, a prediction model construction method and a prediction system, and relates to the technical field of medicine. Factors which are obviously related to blood concentration and have no obvious multicollinearity among variables are screened out from factors influencing pregnancy drug dosage to serve as drug dosage prediction factors, and a corresponding prediction model and system are constructed. According to the screening method, the prediction model construction method and the prediction system provided by the invention, auxiliary decision making can be provided for individualized drug dosage during pregnancy.

The invention belongs to the technical field of pharmaceutical co-crystals, and particularly relates to a synthetic method and application of an amantadine-butylphthalide co-crystal. Butylphthalide reacts to obtain butylphthalide salt or butylphenyltitanic acid, the butylphthalide salt or butylphenyltitanic acid reacts with different substituted amantadine or hydrochloride thereof to synthesize the pharmaceutical co-crystal, and the co-crystal structure can adjust the crystal lattice energy of the pharmaceutical, improve the solubility of the pharmaceutical in water or physiological media, promote the rapid dissolution and absorption of the pharmaceutical in vivo, improve the bioavailability and improve the bioavailability of the pharmaceutical. According to the eutecticum, the problem of solubility of butylphthalide is solved, the formed eutecticum shows certain neuroprotective activity, the biological activity of the eutecticum is remarkably superior to that of a monomer drug, the clinical medication dosage can be reduced while the same treatment effect is achieved, and the eutecticum has certain scientific research value and industrial popularization significance.

The invention relates to the technical field of drug side reaction risk prediction, in particular to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises a data acquisition module used for integrating multi-source time series data, including medication dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; the cumulative effect analysis module is used for calculating a drug attenuation factor, a binding dose and median lethal dose quantitative cumulative effect intensity based on first-order elimination kinetics, and capturing drug metabolic dynamics; due to the fact that the interaction influence effect possibly exists between the drugs, the influence coefficient analysis module is used for adopting elastic network regression and analyzing the drug main effect and the drug combination interaction effect, and determining the main influence coefficient and the interaction influence coefficient of the drugs on each clinical index; and the risk prediction module is used for weighting and optimizing decision tree sorting through the abnormal contribution degree, and outputting the risk probability of each side reaction in combination with a random forest algorithm.

A medication dosage reminder apparatus for displaying dosage information for a medication on a medication container which contains the medication includes a cover configured to be mounted to a medication container. At least one indicator assembly is coupled to the cover to indicate dosage information for a medication stored in the medication container. The indicator assembly is configurable to display a selected dosage indicia.

A system and method for predicting, proposing and / or evaluating suitable medication dosing regimens for a specific individual as a function of individual-specific characteristics and observed responses of the specific individual. Mathematical models of observed patient responses are used in determining an initial dose. The system and method use the patient's observed response to the initial dose to refine the model for use to forecast expected responses to proposed dosing regimens more accurately for a specific patient. More specifically, the system and method uses Bayesian averaging, Bayesian updating and Bayesian forecasting techniques to develop patient-specific dosing regimens as a function of not only generic mathematical models and patient-specific characteristics accounted for in the models as covariate patient factors, but also observed patient-specific responses that are not accounted for within the models themselves, and that reflect variability that distinguishes the specific patient from the typical patient reflected by the model.

The invention provides an intelligent intravenous drug regulation and control system and method, and the system comprises a data collection module which is used for collecting basic parameters and life parameters of a patient; the intelligent decision-making module is used for predicting the medication response of the patient and recommending the medication dosage of the patient based on the basic parameters and the life parameters of the patient; and the execution interaction module is used for automatically generating a doctor's advice based on the patient medication response prediction result and the patient medication dosage recommendation, being linked with a hospital information system and sending an operation prompt to a medical staff terminal. And the aim of improving the individual difference coping ability is fulfilled.

A method of preparing liquid medication doses using an automated dosing device may include securing a vial within a vial holder. The vial includes a liquid medicament. An empty syringe is secured within a syringe holder with a plunger of the syringe being secured by a plunger gripper and a luer lock of the syringe within a luer lock gripper. The syringe holder and the vial holder are moved closer together to insert a needle of the syringe through a septum of the vial while longitudinal axes of the syringe and the vial are at a downward angle and while the vial holder is lower than the syringe holder. The syringe holder and the vial holder are rotated to vertically align the longitudinal axes with the vial holder above the syringe holder. The plunger gripper is pulled away from the luer lock gripper to transfer liquid medicament into the syringe.

Systems, devices, and methods include approaches involving monitoring one or more medication dosages, estimating an analyte level using a chemical sensor that is part of an implantable device or a wearable device, determining an analyte response to the one or more medication dosages, and after the determining, adjusting a medication dose regimen.

The invention discloses an artificial intelligence-driven personalized drug dosage dynamic adjustment method and system. The method comprises the following steps: acquiring multi-source heterogeneous data of a patient, preprocessing and constructing to obtain graph structure data; performing feature extraction on the graph structure data by using a trained graph convolutional network to obtain high-order features of the patient, and predicting treatment conditions of the patient under different dose combinations; based on the high-order features, searching an optimal dose combination in a medication dose solution space by using an improved genetic algorithm, and generating a medication dose adjustment scheme; generating a risk assessment report based on the drug dosage adjustment scheme in combination with the multi-source heterogeneous data, and prompting the potential risk of dosage adjustment; and continuously collecting subsequent treatment feedback data of the patient and using the subsequent treatment feedback data to optimize the parameters of the graph convolutional network and the weight of the fitness function in the improved genetic algorithm. According to the method, the precision and dynamic adjustment of the medication dosage are realized.

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

A device may include a dispensing device configured to contain a medicine. A device may include a visual dosing aid on a surface of the dispensing device, the visual dosing aid comprising a plurality of dosing segments, wherein: the visual dosing aid is correlated with a physical parameter, the plurality of dosing segments correspond to a particular volume of the medicine; and the particular volume of the medicine matches a medication dose associated with the physical parameter.

The present application relates to the technical field of drug side reaction risk prediction, and particularly relates to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises: a data acquisition module for integrating multi-source time series data, including drug dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; a cumulative effect analysis module for calculating a drug attenuation factor based on first-order elimination kinetics, quantifying the cumulative effect intensity in combination with the dosage and median lethal dose, and capturing the drug metabolism dynamics; since there may be interactive effects between drugs, an influence coefficient analysis module is used to analyze the drug main effect and the joint drug interaction effect by using elastic network regression, and to determine the main influence coefficient and the interaction influence coefficient of the drug on each clinical index; a risk prediction module for optimizing the decision tree sorting by the abnormal contribution degree weighting, and outputting the risk probability of each side reaction in combination with the random forest algorithm.

The utility model provides an enemator with a leakage-proof structure, which belongs to the field of medical instruments and comprises a medicine cylinder, an enema component and a fixing component. A piston in the medicine cylinder is connected with a medicine injection push rod; one end of the medicine cylinder is connected with a medicine outlet pipe; the leakage-proof tube is arranged at one end of the medicine outlet tube, the movable plug opening is rotatably installed at one end of the leakage-proof tube, after enema and medicine injection are conducted on a patient through the leakage-proof tube, the air bag is inflated through the inflation tube, the air bag is inflated and swelled to fix the leakage-proof tube in the body of the patient, and the air bag can play a role in blocking and preventing medicine from flowing out. For a patient whose anal sphincter relaxation enema medicine cannot be reserved in the intestinal tract, the medicine can be well reserved in the intestinal tract, the purpose of intestinal tract treatment is achieved, for a patient whose intestinal tract disease needs to be treated with enema liquid, the leakage-proof tube can be reserved in the anus through the air bag to inject the medicine for multiple times, the medicine can be prevented from flowing out, and the accuracy of the dosage can be guaranteed.

The invention discloses a tumor patient individualized medication dose optimization method, which comprises the following steps: establishing a patient file, calculating an initial dose based on evidence-based knowledge, making a structured follow-up visit plan, integrating data from communities, families and patient reports, analyzing by using a fusion rule and an intelligent algorithm, and generating a dose optimization suggestion. After doctor-patient auditing, a situational medication reminding and recording tool is automatically updated and pushed, and finally continuous loop feedback and iteration of a treatment scheme are achieved; according to the invention, long-term follow-up visit and dosage decision are bound, and medication reminding, patient education and clinical support are combined, so that real-time, accurate and individualized adjustment of the medication dosage is effectively realized in a basic scene, and the treatment safety and compliance are improved.

The invention discloses an ICU (intensive care unit) medicine intelligent blending and information management system, which relates to the technical field of intelligent medical treatment and comprises a data acquisition module, a data integration module, a dose calibration module, a consumption analysis module and an inventory management module. Multi-modal physiological sign data of an ICU patient are collected in real time through the data collection module and preprocessed into standardized physiological sign data, the data integration module is connected with the electronic medical record system to extract clinical basic data and basic sign baseline data, and a unified diagnosis and treatment data set is formed through correlation and integration. The dosage calibration module calculates the adjusted individualized medication dosage and generates an individualized medication instruction on the basis of the unified diagnosis and treatment data set in combination with clinical medication specifications and physical sign fluctuation-dosage adjustment rules, so that the medication dosage is accurately matched with the individual characteristics of the patient and real-time illness state changes, medicine allocation better meets the diagnosis and treatment requirements of the ICU patient, and the diagnosis and treatment efficiency of the ICU patient is improved. And the limitation of a fixed dose scheme is avoided.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

A wearable heads-up display (“HUD”) for a pharmacy workflow management system is disclosed herein. An example HUD includes smart-glasses that are communicatively coupled to a client device. The smart-glasses include at least one camera and / or barcode scanner to record verification information needed for the verification of a medication dose during medication formulation preparation. Further, the smart-glasses include at least one embedded display screen that shows sequential steps of a preparation protocol for guiding a pharmacy technician to prepare a medication dose. An application on the client device and / or the smart-glasses is configured to record the verification information obtained from the camera and / or barcode scanner for remote verification to ensure the medication dose was prepared properly.

Systems, devices, and methods include approaches involving monitoring one or more medication dosages; estimating an analyte level using a chemical sensor that is part of an implantable device or a wearable device; determining an analyte response to the one or more medication dosages; and, after the determining, adjusting a medication dose regimen.

A syringe holder for facilitating dispensing of medication to a patient from a syringe. The syringe holder includes a cylindrical housing configured to be attached to a barrel portion of the syringe. A first visual dosing aid on a surface of the cylindrical housing is of a first color and has a plurality of first dosing segments where the first color is correlated to a first patient size. Each of the first dosing segments identifies a volume of the medication corresponding to a first medication dose. A second visual dosing aid on a surface of the cylindrical housing is of a second color and has a plurality of second dosing segments where the second color is correlated to a second patient size. Each of the second dosing segments identifies a volume of the medication corresponding to a second medication dose.